BiotechTube

SHR0410

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus

Trial Timeline

Jul 28, 2019 โ†’ Jun 15, 2020

NCT ID
NCT04099927

About SHR0410

SHR0410 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04099927. Target conditions include Pruritus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04099927Phase 1Completed

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
44
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
33
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
52
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
76
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
51
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
76
BLU-5937 + PlaceboGSK plcPhase 2
51
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
51
REGN846Regeneron PharmaceuticalsPhase 1/2
40
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I:HSK21542 0.05 ฮผg/kg + Stage I:HSK21542 0.15 ฮผg/kg + Stage I:HSK21542 0.30 ฮผg/kg + Stage I:HSK21542 0.80 ฮผg/kg + Stage II:HSK21542 0.3 ฮผg/kg + Stage II:HSK21542 0.6 ฮผg/kgHaisco Pharmaceutical GroupPhase 2
49
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
28
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
44
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
25
Serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85